Orexo AB (publ) – OTC:ORXOY

Orexo AB (publ) stock price today

$1.91
+0.03
+1.6%
Financial Health
0
1
2
3
4
5
6
7
8
9

Orexo AB (publ) stock price monthly change

-11.32%
month

Orexo AB (publ) stock price quarterly change

-11.32%
quarter

Orexo AB (publ) stock price yearly change

+21.29%
year

Orexo AB (publ) key metrics

Market Cap
59.69M
Enterprise value
479.05M
P/E
-3.46
EV/Sales
0.78
EV/EBITDA
-8.11
Price/Sales
0.84
Price/Book
1.72
PEG ratio
-0.26
EPS
-2.14
Revenue
619.1M
EBITDA
27.7M
Income
-73.4M
Revenue Q/Q
-12.27%
Revenue Y/Y
-0.72%
Profit margin
-24.8%
Oper. margin
-28.88%
Gross margin
84.14%
EBIT margin
-28.88%
EBITDA margin
4.47%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Orexo AB (publ) stock price history

Orexo AB (publ) stock forecast

Orexo AB (publ) financial statements

Orexo AB (publ) (OTC:ORXOY): Profit margin
Jun 2023 157.7M -12.6M -7.99%
Sep 2023 156.1M -33.3M -21.33%
Dec 2023 166M -18.6M -11.2%
Mar 2024 139.3M -8.9M -6.39%
Orexo AB (publ) (OTC:ORXOY): Debt to assets
Jun 2023 926900000 803.1M 86.64%
Sep 2023 869000000 777M 89.41%
Dec 2023 786600000 727.7M 92.51%
Mar 2024 829900000 768.5M 92.6%
Orexo AB (publ) (OTC:ORXOY): Cash Flow
Jun 2023 -12.7M 125.1M -14M
Sep 2023 -21.9M -6.6M -39.1M
Dec 2023 -2.6M -900K -5.5M
Mar 2024 -18.9M -1.2M 43.3M

Orexo AB (publ) alternative data

Orexo AB (publ) (OTC:ORXOY): Employee count
Aug 2023 126
Sep 2023 120
Oct 2023 120
Nov 2023 120
Dec 2023 118
Jan 2024 118
Feb 2024 118
Mar 2024 116
Apr 2024 116
May 2024 116
Jun 2024 116
Jul 2024 113

Orexo AB (publ) other data

  • What's the price of Orexo AB (publ) stock today?

    One share of Orexo AB (publ) stock can currently be purchased for approximately $1.91.

  • When is Orexo AB (publ)'s next earnings date?

    Unfortunately, Orexo AB (publ)'s (ORXOY) next earnings date is currently unknown.

  • Does Orexo AB (publ) pay dividends?

    No, Orexo AB (publ) does not pay dividends.

  • How much money does Orexo AB (publ) make?

    Orexo AB (publ) has a market capitalization of 59.69M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 2.32% to 638.8M US dollars.

  • What is Orexo AB (publ)'s stock symbol?

    Orexo AB (publ) is traded on the OTC under the ticker symbol "ORXOY".

  • What is Orexo AB (publ)'s primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers—Specialty & Generic industry.

  • How do i buy shares of Orexo AB (publ)?

    Shares of Orexo AB (publ) can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Orexo AB (publ) have?

    As Jul 2024, Orexo AB (publ) employs 113 workers, which is 3% less then previous month and 3% less then previous quarter.

  • When Orexo AB (publ) went public?

    Orexo AB (publ) is publicly traded company for more then 11 years since IPO on 9 Sep 2013.

  • What is Orexo AB (publ)'s official website?

    The official website for Orexo AB (publ) is orexo.com.

  • How can i contact Orexo AB (publ)?

    Orexo AB (publ) can be reached via phone at +46 18 780 88 00.

Orexo AB (publ) company profile:

Orexo AB (publ)

orexo.com
Exchange:

OTC

Full time employees:

126

Industry:

Drug Manufacturers—Specialty & Generic

Sector:

Healthcare

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.

Virdings allE 32 A
Uppsala, 751 05

:
ISIN: US68616W1027
: